-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From November 5 to 12, 2022, the "Chinese Society of Clinical Oncology (CSCO) Annual Conference Academic Week" was held
in five cities: Beijing, Shanghai, Guangzhou, Harbin and Jinan.
At the meeting, Qilu Pharmaceutical announced the latest results
of its phase II study of the new combination antibody QL1706 in the form of posters.
This study aimed to assess the safety and efficacy
of QL1706 in combination with paclitaxel-cisplatin/carboplatin plus or without bevacizumab for the first-line treatment of relapsed or metastatic cervical cancer.
The research was led by President Wang Danbo of Liaoning Cancer Hospital and Director Liu Naifu of Shandong Cancer Hospital, and was carried out
in 13 clinical research centers in China.
The data showed that patients with relapsed or metastatic cervical cancer who had not received systemic therapy received QL1706 combined with chemotherapy with or without bevacizumab had an objective response rate (ORR) of 77.
2%.
Worldwide, cervical cancer has the highest incidence and mortality among women
.
More than half of patients have already progressed to the disease at the time of diagnosis and have lost the opportunity for radical surgery and require systemic anti-tumor therapy
.
QL1706 is a novel therapeutic combination antibody
developed by Qilu Pharmaceutical's MabPair technology platform that simultaneously targets dual immune checkpoints of programmed death receptor 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4).
The results of previous clinical studies showed that QL1706 monotherapy in the treatment of relapsed/metastatic cervical cancer initially showed good efficacy and safety
.
The study reported was an open-label, non-randomized, multicenter phase II study
.
Patients with relapsed or metastatic cervical cancer who had not previously received systemic treatment were studied
.
A total of 60 patients were enrolled and treated in 2 cohorts: QL1706 in combination with chemotherapy versus QL1706 in combination with chemotherapy + bevacizumab
.
It is administered 1 time every
3 weeks.
After completing 6 cycles of chemotherapy, chemotherapy can be stopped and continued with QL1706 with or without bevacizumab until disease progression or toxicity intolerance
.
The results suggest that QL1706 in combination with chemotherapy plus or without bevacizumab is safe and expected in the first-line treatment of relapsed or metastatic cervical cancer
.
The most common adverse reaction was a decrease in white blood cell count (48.
3%), followed by anemia (33.
3%)
.
The incidence of serious adverse reactions was 20%.
The incidence of immune-related adverse reactions was 23.
3%.
QL1706 in combination with chemotherapy plus or without bevacizumab in the first-line treatment of relapsed or metastatic cervical cancer shows excellent antitumor activity
.
A total of 57 patients were included in the efficacy analysis, with an ORR of 77.
2% and a disease control rate of 98.
2%.
By the time of data cut-off, median progression-free survival (PFS) and overall survival (OS) data were not mature
.
At present, based on the results of this study, a phase III clinical study
has been conducted to evaluate the efficacy and safety of QL1706 in combination with paclitaxel-cisplatin/carboplatin plus or without bevacizumab in the first-line treatment of relapsed or metastatic cervical cancer.
